TITLE

Third-Line Chemotherapy in Small-Cell Lung Cancer: An International Analysis

AUTHOR(S)
Simos, Demetrios; Sajjady, Golmehr; Sergi, Melissa; Mun Sem Liew; Califano, Raffaele; Ho, Cheryl; Leighl, Natasha; White, Shane; Summers, Yvonne; Petrcich, William; Wheatley-Price, Paul
PUB. DATE
March 2014
SOURCE
Clinical Lung Cancer;Mar2014, Vol. 15 Issue 2, p110
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
94754944

 

Related Articles

  • Adjuvant Chemotherapy with Cisplatin for Lung Cancer. Zepf, Bill // American Family Physician;9/1/2004, Vol. 70 Issue 5, p978 

    Deals with the use of adjuvant chemotherapy with cisplatin for lung cancer. Standard of care in the treatment of non-small-cell lung cancer.

  • Small-cell lung cancer in elderly patients: The case for chemotherapy. Kelly, P.; O'Brien, A.A.J. // Age & Ageing;Jan1991, Vol. 20 Issue 1, p19 

    Details a retrospective analysis of survival in 48 elderly and 70 young patients with small-cell lung cancer. Similar survivability with combination chemotherapy with old and young subjects; Peripheral neuropathy secondary to vincristine and elderly subjects; Small-cell lung cancer and smoking;...

  • Chemotherapy costs worth it for NSCLC in the UK.  // PharmacoEconomics & Outcomes News;9/10/2005, Issue 486, p9 

    Discusses research being done on the estimation of the additional costs of chemotherapy for patients with advanced non-small cell lung cancer. Technique used in estimating the cost of chemotherapy; Results of the cost analysis.

  • Lung cancer drug therapy in Hungary - 3-year experience. Moldvay, Judit; Rokszin, György; Abonyi-Tóth, Zsolt; Katona, Lajos; Fábián, Katalin; Kovács, Gábor // OncoTargets & Therapy;2015, Vol. 8, p1031 

    Hungary is a world leader in lung cancer deaths, so it is of crucial importance that patients have access to modern treatments. The aim of our analysis was to explore how drug treatments are used in Hungary and how they are compatible with international practice. The inpatient and prescription...

  • Lung Cancer.  // Current Medical Literature: Respiratory Medicine;2009, Vol. 23 Issue 3, p74 

    The article summarizes studies related to lung cancer. The study "Cetuximab Plus Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer (FLEX): An Open-Label Randomised Phase III Trial," by R. Pirker et al assessed patients with stage IIIB or stage IV non-small-cell lung cancer. It...

  • Survival and lung cancer.  // Thorax;Dec2007 Supp, Vol. 62, pA33 

    The article presents abstracts on medical topics which include the effect of pre-operative chemotherapy in patients with resectable non-small cell lung cancer, analysis of a lung cancer cohort for variation in survival over a seven-year period and the importance of patients without histological...

  • Third-Line Therapy for Advanced Non-Small-Cell Lung Cancer Patients: A Feasible Therapeutic Option? Galetta, Domenico; Rossi, Antonio; Colucci, Giuseppe; Gebbia, Vittorio // Oncology;2009 Supplement 1, Vol. 77, p113 

    Two decades ago best supportive care was considered a valid therapeutic option for advanced non-small cell lung cancer (NSCLC) patients until the evidence derived from meta-analysis showed symptom improvement and a survival advantage from systemic chemotherapy. A further advantage was reported...

  • Erlotinib breathes new life into NSCLC treatments. Sullivan, Suzanne // PharmacoEconomics & Outcomes News;11/18/2006, Issue 516, p3 

    The article highlights the studies presented at the 9th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research on the cost effectiveness of erlotinib as second- or third-line strategy for the treatment of non-small-cell lung cancer (NSCLC). The...

  • A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in... Roth, Jack A.; Fossella, Frank // JNCI: Journal of the National Cancer Institute;5/4/94, Vol. 86 Issue 9, p673 

    Presents a study of patients with previously untreated, potentially resectable clinical stage IIIA non-small-cell lung cancer to compare the results of perioperative chemotherapy and surgery with those of surgery alone. Analysis of survival and recurrences.

  • Medical oncology.  // Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS58 

    Presents an abstract of the research manuscript `Cost-utility analysis of newer chemotherapy regimens for advanced non-small cell lung cancer,' by C. Earle et al.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics